0001140361-23-054514.txt : 20231122 0001140361-23-054514.hdr.sgml : 20231122 20231122192722 ACCESSION NUMBER: 0001140361-23-054514 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231030 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GNI Group Ltd. CENTRAL INDEX KEY: 0001958461 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 231434783 BUSINESS ADDRESS: STREET 1: NIHONBASHI-HONCHO YS BLDG 3F STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-0023 BUSINESS PHONE: 81-3-6214-3600 MAIL ADDRESS: STREET 1: NIHONBASHI-HONCHO YS BLDG 3F STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-0023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GNI USA, Inc. CENTRAL INDEX KEY: 0001973229 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 231434782 BUSINESS ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-284-0324 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562020050 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (619) 949-3681 MAIL ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC. DATE OF NAME CHANGE: 20150820 FORMER COMPANY: FORMER CONFORMED NAME: TARGACEPT INC DATE OF NAME CHANGE: 20000919 4 1 form4.xml X0508 4 2023-10-30 0001124105 GYRE THERAPEUTICS, INC. GYRE 0001958461 GNI Group Ltd. NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023 JAPAN true 0001973229 GNI USA, Inc. 12730 HIGH BLUFF DRIVE SUITE 250 SAN DIEGO CA 92130 true false Common Stock 2023-10-30 4 J 0 63588119 A 64005887 I See Remarks Represents the number of shares of common stock of the Issuer received by the Reporting Person in exchange for the shares of Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares ("CPI") and Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271, held by the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation, [cont'd from FN 1] GNI USA, Inc., a Delaware corporation ("GNI USA"), the Reporting Person, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and CPI. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China. These securities are held by GNI USA which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA. /s/ Branden Berns, as attorney-in-fact for GNI Group Ltd. 2023-11-22 /s/ Branden Berns, as attorney-in-fact for GNI USA, Inc. 2023-11-22